The global antifungal medicine market is anticipated to increase at a significant CAGR over the forecast period due to rise in global population, and unhygienic environment. Burgeoning prevalence of infectious diseases, hospital acquired infections (nosocomial infections) coupled with rising awareness about the myriad fungal infections, and rising awareness of over-the-counter (OTC) antifungal medicine are the key factors expected to fuel the growth of the antifungal medicine market. In addition, rise in the R&D expenditure, increased funding from private and public sector for dermal infections, higher prevalence of chronic conditions, including HIV and cancer, rising of immunocompromised population, and increase in awareness by organizing patient education program are boosted the growth of antifungal medicine market over forecast period. A sample of this report is available upon request @
[URL] https://www.precisionbusinessinsights.com/wp-content/uploads/2017/09/Global-Anti-fungal-Drugs-Market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
The antifungal medicine market is segmented on the basis of drug class, route of administration, therapeutic indication, and distribution channel
Based on the drug class, antifungal medicine market is segmented into the following:
Azoles
Polyenes
Echinocandins
Allylamines
Others
Based on the route of administration, antifungal medicine market is segmented into the following:
Oral
Parenteral
Topical
Based on therapeutic indications, antifungal medicine market is segmented into the following:
Aspergillosis
Candidiasis
Dermatophytosis
Others
Based on distribution channel, antifungal medicine market is segmented into the following:
Retail pharmacies
Hospital pharmacies
Drug stores
Online pharmacies
To view TOC of this report is available upon request @
[URL] https://www.precisionbusinessinsights.com/wp-content/uploads/2017/09/Global-Anti-fungal-Drugs-Market/#ulp-c654SbFYO64MsOhu[/URL]
The global antifungal medicine market is in blooming stage, several local and international players are actively involved in the development of antifungal medicine. The collaboration of government organizations for the increase in the awareness about fungal infections is expected to unlock the potential of antifungal medicine market. For instance, In November 2013, the CDC entered into a collaborative agreement with the National Health Ministry to enhance the treatment rates of communicable diseases in emerging countries, such as Brazil and India.
Need more information about this report @
[URL] https://www.precisionbusinessinsights.com/wp-content/uploads/2017/09/Global-Anti-fungal-Drugs-Market/#ulp-14mlyhjMGhVjZqa3[/URL]
Some of the players in antifungal medicine market are Pfizer, Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), GlaxoSmithKline plc. (U.K.), Mylan N.V. (U.S.), Tecan Group (Switzerland), and AureoGen Biosciences Inc. (U.S.), to name a few.
"Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553